13.10

1.13% -0.18

Korro Bio Inc (KRRO)

Overview News Price History Discussions Forecast

Korro Bio Inc stock is traded at $13.10, with a volume of 53,463. It is down -1.13% in the last 24 hours and up +7.18% over the past month. Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Previous Close:

$13.28

Open:

$13.11

24h Volume:

53,463

Relative Volume:

0.28

Market Cap:

$193.05M

Revenue:

$6.39M

Net Income/Loss:

$-117.26M

P/E Ratio:

-1.0496

EPS:

-12.4807

Net Cash Flow:

$-79.08M

1W Performance:

-2.67%

1M Performance:

+7.18%

6M Performance:

+14.37%

1Y Performance:

-35.19%

1-Day Range:

$12.88

$13.72

1-Week Range:

$12.72

$14.00

52-Week Range:

$5.2044

$55.89

Korro Bio Inc Stock (KRRO) Company Profile

Name

Korro Bio Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

617-468-1999

Address

60 FIRST STREET, CAMBRIDGE

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

KRRO's Discussions on Twitter

Compare KRRO vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRRO Korro Bio Inc	13.11	195.56M	6.39M	-117.26M	-79.08M	-12.48
VRTX Vertex Pharmaceuticals Inc	515.07	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.80	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.57	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.87	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.09	39.31B	5.76B	514.49M	1.10B	4.4813

Korro Bio Inc Stock (KRRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-26	Upgrade	Raymond James	Mkt Perform → Outperform
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-29-26	Upgrade	Chardan Capital Markets	Neutral → Buy
Jan-29-26	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-29-26	Upgrade	Piper Sandler	Neutral → Overweight
Jan-28-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jan-28-26	Upgrade	Oppenheimer	Perform → Outperform
Nov-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-13-25	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-13-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-25	Downgrade	Piper Sandler	Overweight → Neutral
Nov-13-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-13-25	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-13-25	Downgrade	William Blair	Outperform → Mkt Perform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-16-25	Initiated	Chardan Capital Markets	Buy
Jan-10-25	Initiated	Oppenheimer	Outperform
Oct-21-24	Initiated	Raymond James	Strong Buy
Aug-14-24	Initiated	William Blair	Outperform
Mar-28-24	Reiterated	H.C. Wainwright	Buy
Feb-27-24	Initiated	BMO Capital Markets	Outperform
Dec-04-23	Initiated	H.C. Wainwright	Buy
Nov-29-23	Initiated	RBC Capital Mkts	Outperform
Nov-10-23	Initiated	Piper Sandler	Overweight
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-22-20	Initiated	B. Riley Securities	Buy
Jul-14-20	Initiated	Oppenheimer	Outperform
May-18-20	Downgrade	JP Morgan	Overweight → Neutral
Oct-28-19	Initiated	Cowen	Outperform
Oct-28-19	Initiated	Goldman	Buy
Oct-28-19	Initiated	JP Morgan	Overweight

View All

Korro Bio Inc Stock (KRRO) Latest News

06:32 AM

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

06:32 AM

Aug 13, 2026

Insider Selling: Korro Bio (NASDAQ:KRRO) Director Sells $29,916.28 in Stock - MarketBeat

Aug 13, 2026

Korro Bio director Jean Francois Formela sells $29,916 in shares - Investing.com

Aug 13, 2026

Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan

Aug 13, 2026

Lynx1 Capital Management Lp Buys 5,222 Shares of Korro Bio (NASDAQ:KRRO) Stock - MarketBeat

Aug 13, 2026

Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock - Investing.com

Aug 13, 2026

Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock By Investing.com - Investing.com Canada

Aug 13, 2026

Korro Bio (KRRO) holder Lynx1 Capital reports 6,684-share indirect stock purchase - Stock Titan

Aug 13, 2026

Aug 11, 2026

HC Wainwright Has Strong Estimate for Korro Bio Q3 Earnings - MarketBeat

Aug 11, 2026